Norway - Medical equipments, pharmaceuticals and personal care products - Medicine and multi-dose - MARKET DIALOGUE

Trondheim municipality, hereafter called the Contracting Authority, is working on acquiring a new framework agreement for medicines and multi-dose applicable from 01.01.2027 to the municipality ́s units and to cooperating contract municipalities (i.a. Bergen, Stavanger and Kristiansand municipalities) with accompanying collaboration partners (a total of approx. 75 contracting authorities). See the overview of the contract and collaboration municipalities from 2022 in annex 2. Whether the dialogue dialogue will take place in writing with an introductory round (first question/answer), then the hearings and/or questions that we publish as additional information under the "Communication" tab. There will be relatively short reply deadlines, and replies received after this cannot be expected to be taken into account in the work with the procurement. In some cases it may also be necessary to contact one or several tenderers, e.g. for further clarifications or additional information. ScheduleWe plan for the following progress in the procurement: Week 35 - 36: Market dialogue - first question / answerUke 37 - 41: First revision of requirements, Criteria and contract provisionsUke 44: Consultation round 1Uke 45-47: Other revisions of requirements, criteria and contract provisionsUke 48: Hearing round 2Uke 49: Third revision of requirements, criteria and contract provisionsUke 2 (2026): Announcement of competition basis from 2022 Attached are requirements, criteria and contract provisions that were used in 2022. These will form the basis for many questions, particularly the first question/answer. First question/answerIn the first run, we would like feedback on the questions in the attached document named Answer Form - Market Dialogue - Medicine and Multi-Dose - first question/answer. The deadline for responding to this is Thursday 04.09.2025, 15.00.Vi thank you in advance for all input and constructive proposals.